Compare Allstate Corp (ALL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs BioNano Genomics Inc — how do they compare? Allstate Corp trades at $254.71 (market cap $64.77B), while BioNano Genomics Inc trades at $1.17 (market cap $13.77M). The key difference: Allstate Corp is far larger — about 4703.7× BioNano Genomics Inc's market cap, and Allstate Corp pays a 1.72% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ALL | BNGO | |
|---|---|---|
Market Cap | $64.77B | $13.77M |
Sector | Financials | Health |
52-Week High | $251.61 | $4.92 |
52-Week Low | $190.00 | $1.09 |
Enterprise Value | $73.56B | $16.38M |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
BNGO trades at $1.20, up 5.26% today, but technical signals are bearish with moving averages indicating selling pressure. The company reported a net loss of -$26.40M in 2025 despite beating EPS estimates in recent quarters. Recent news highlights leadership changes and growing adoption of its optical genome mapping technology, with 67% year-over-year growth in studies presented at ESHG 2026 (GlobeNewswire, June 18, 2026).
The outlook remains challenged by persistent losses and negative cash flow, though low valuation ratios (P/S 0.31, P/B 0.37) may attract value investors. Analyst sentiment is cautiously optimistic with 57% buy ratings, but execution risks and profitability concerns pose significant headwinds for near-term stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
